SCHEMBL5230183

SCHEMBL5230183

COc1ccc(-n2nc(C#N)c3ccc4[nH]ncc4c32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
HTT P42858 2/20 0.46
RAB9A P51151 2/20 0.46
LMNA P02545 2/20 0.46
OPRK1 P41145 1/20 0.46
CCNA2 P20248 3/20 0.39
CDK2 P24941 3/20 0.39
CCNA1 P78396 3/20 0.39
USP7 Q93009 1/20 0.39
TRPV1 Q8NER1 1/20 0.38
TP53 P04637 1/20 0.35
F10 P00742 4/20 0.35
GAA P10253 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPKAPK2 P49137 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228034 0.81 GAA (0.44) MAPTALDH1A1LMNACCNA2CDK2
SCHEMBL5230295 0.78 CCNA2 (0.53) MAPTALDH1A1CCNA2CDK2CCNA1
SCHEMBL5228781 0.77 CCNA2 (0.54) MAPTALDH1A1CCNA2CDK2CCNA1
SCHEMBL5225978 0.76 CDK2 (0.42) MAPTSMN1; SMN2NPC1RAB9ACCNA2
SCHEMBL12886440 0.75 CDK2 (0.46) ALDH1A1SMN1; SMN2NPC1RAB9ACCNA2
SCHEMBL5228553 0.75 CDK2 (0.44) MAPTALDH1A1NPC1RAB9ACCNA2
SCHEMBL5225870 0.75 CDK2 (0.56) ALDH1A1SMN1; SMN2NPC1RAB9ACCNA2
SCHEMBL5228539 0.75 CCNA2 (0.43) MAPTALDH1A1CCNA2CDK2CCNA1
SCHEMBL5227842 0.75 CCNA2 (0.43) MAPTALDH1A1CCNA2CDK2CCNA1
SCHEMBL5229147 0.74 CCNA2 (0.56) MAPTALDH1A1SMN1; SMN2NPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1478357-B1 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-01-31 EP claimed
US-20050176796-A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2005-08-11 US claimed
EP-1478357-B1 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-01-31 EP disclosed
US-20050176796-A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176796-A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents TP53, NFATC1, MAP3K15 MAPT 41/4885ALDH1A1 4396/4885SMN1; SMN2 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.